Biogen Inc. Form 8-K Summary: Acquisition of Apellis Pharmaceuticals
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 14, 2026, details the consummation of Biogen Inc.'s acquisition of Apellis Pharmaceuticals, Inc. The transaction was finalized on May 14, 2026, following a tender offer that expired on May 13, 2026. Biogen has entered into a definitive merger agreement and executed a new credit facility to fund the transaction.
Key Financial Metrics and Transaction Terms
- Transaction Value: The aggregate amount to be paid for the Offer and Merger is approximately $5.3 billion, excluding fees and potential Contingent Value Rights (CVR) payments.
- Consideration Structure: Shareholders received $41.00 per share in cash plus one CVR per share.
- Debt Financing: Biogen entered into a $2 billion unsecured term loan credit agreement on May 12, 2026, and borrowed the full amount on May 13, 2026.
- Tranche A: $1 billion, 364-day maturity (due May 12, 2027).
- Tranche B: $1 billion, two-year maturity (due May 12, 2028).
- Contingent Liability: Biogen estimates a potential maximum aggregate payment of approximately $582 million for CVRs if all milestones are achieved.
- Participation: 105,687,831 shares were validly tendered, representing approximately 82.4% of outstanding shares.
Material Changes and Milestones
The primary material change is the acquisition of Apellis, making it a wholly-owned subsidiary of Biogen. The transaction introduces significant contingent liabilities based on the future performance of Apellis's product SYFOVRE®:
- Net Sales Milestone 1: $2.00 per CVR if Annual Net Sales of SYFOVRE® reach at least $1.5 billion in any calendar year from 2027 to 2030.
- Net Sales Milestone 2: $2.00 per CVR if Annual Net Sales reach at least $2.0 billion in any calendar year from 2027 to 2031. If Milestone 1 is not met by December 31, 2030, but Milestone 2 is met in 2031, the payment increases to $4.00 per CVR.
- Debt Covenants: The new credit agreement requires Biogen to maintain a maximum consolidated leverage ratio of 3.75 to 1.0, temporarily extendable to 4.25 to 1.0 for material acquisitions.
Outlook, Risks, and Management Commentary
Biogen has confirmed the completion of the merger and the acceptance of all validly tendered shares. The company utilized a combination of cash and the new $2 billion borrowings to fund the transaction. There is no assurance that the CVR milestones will be achieved prior to the expiration of the CVR Agreement. The filing notes that pro forma financial information will be filed by amendment within 71 calendar days. The transaction is subject to customary representations, warranties, and events of default.
Key Facts for Investor Verification
- Verify the exact number of shares tendered and the final cash consideration paid versus the estimated $5.3 billion aggregate.
- Review the full text of the CVR Agreement (Exhibit 10.1) to understand the specific definitions of "Annual Net Sales" and the conditions for the $582 million potential payout.
- Monitor Biogen's leverage ratio compliance under the new 3.75 to 1.0 covenant, especially given the immediate addition of $2 billion in debt.
- Check the upcoming pro forma financial information filing to assess the combined entity's liquidity and debt service capabilities.
- Confirm the treatment of Apellis equity awards and the specific vesting conditions for unvested options and RSUs post-merger.